Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
Fiche publication
Date publication
juillet 2022
Journal
Journal for immunotherapy of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana, Dr CAILLOT Denis, Pr DECONINCK Eric, Dr FERRAND Christophe, Dr DESCHAMPS Marina, Dr DAGUINDAU Etienne
Tous les auteurs :
Trad R, Warda W, Alcazer V, Neto da Rocha M, Berceanu A, Nicod C, Haderbache R, Roussel X, Desbrosses Y, Daguindau E, Renosi F, Roumier C, Bouquet L, Biichle S, Guiot M, Seffar E, Caillot D, Depil S, Robinet E, Salma Y, Deconinck E, Deschamps M, Ferrand C
Lien Pubmed
Résumé
Acute myeloid leukemia (AML) remains a very difficult disease to cure due to the persistence of leukemic stem cells (LSCs), which are resistant to different lines of chemotherapy and are the basis of refractory/relapsed (R/R) disease in 80% of patients with AML not receiving allogeneic transplantation.
Mots clés
T-lymphocytes, cytotoxicity, immunologic, hematologic neoplasms, immunotherapy
Référence
J Immunother Cancer. 2022 07;10(7):